Joint Formulary & PAD

Botulinum toxin type A - Hypersalivation in children

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Not Specified
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

Not assessed for formulary status. Contact pharmacy to make a formulary application.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Botulinum toxin type A
Indication :
Hypersalivation in children
Group Name :
Keywords :
MND, acquired brain injury, neurodisability, cerebral palsy, long term ventilation, drooling, drug-induced hypersalivation, sialorrhea, botox
Brand Names Include :
Xeomin, Botox, Dysport
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Drugs

Below are listed other drugs that are used to treat Hypersalivation in children.

Committee Recommendations (1)

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicans can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.